EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hemostatic Considerations of New Treatment Options for Hemophilia During Surgery, Infection, and Bleeding in Children and Adolescents

Ivonne Wieland, Katharina Becker

Hämostaseologie · 2026-10 · 46 (05) · 317-325

DOI: 10.1055/a-2957-0168 ↗
AbstractBibliografische Angaben

Abstract

Abstract In recent years, the therapeutic landscape for hemophilia has changed significantly, with the approval of several innovative agents, some featuring entirely novel mechanisms of action. These advances have substantially improved outcomes and reduced the treatment burden. However, clinical experience with these novel therapies in special situations—such as bleeding, surgery, trauma, and infection—remains limited. Factor replacement therapy has been the standard of care for a long time, with extensive clinical experience. The introduction of non-factor therapies has raised important questions: Is additional treatment required after injury or during surgery? What are the considerations in cases of sepsis or disseminated intravascular coagulation (DIC)? This summary focuses on emicizumab, efanesoctocog alfa, newly approved TFPI inhibitors, nonacog beta pegol, and the extension of indications for PEGylated FVIII preparations to younger age groups. We will therefore also briefly address these developments. The largest part of this manuscript will focus on emicizumab due to its longer approval history and the most extensive data available. Most other medications were licensed in 2024 or later.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →